文献速递针灸推拿中医康复

针灸治疗化疗诱导周围神经病变的成本效果分析

Economic evaluation alongside a randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy.
PubMed 文献 · Acupunct Med · 2020-05-13

OBJECTIVE: To assess the cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy (CIPN) in Hong Kong.…

要点

  • 针灸可改善CIPN疼痛强度与干扰,14周内疼痛评分变化优于常规护理。
  • 针灸组与常规护理组QALY均值变化分别为0.209和0.200,差异甚微。
  • 各视角ICER均远超香港基础分析所用成本效果阈值HK$180,450/QALY。

核心结论

  • 针灸可改善CIPN相关疼痛与生活质量指标,但在资源有限医疗系统中不太可能具成本效果。

研究设计与样本

  • 次要成本效果分析以简明疼痛量表(BPI)疼痛变化为终点。

主要发现

  • 针灸组疼痛强度8周和14周平均变化较常规护理分别为-1.8和-1.8。
  • 针灸组疼痛干扰8周和14周平均变化较常规护理分别为-1.5和-0.9。
  • 针灸组与常规护理组QALY均值变化分别为0.209和0.200。
  • 确定性ICER分别为每获得一个QALY:卫生服务提供者视角HK$616,965.62、社会视角HK$824,083.44、患者视角HK$540,727.56。

关键数值与推荐

  • 基础分析所用成本效果阈值为HK$180,450/QALY,各视角ICER均显著高于该阈值。
  • 疼痛强度与干扰以BPI测量,8周和14周均值变化均较常规护理下降。

临床怎么用

  • 在资源有限医疗系统中,针灸改善CIPN症状的获益可能不足以支持其作为具成本效果的常规治疗。
  • 临床决策需结合症状改善与支付方成本效果阈值综合考量。

局限性

  • 经济评价主要基于14周治疗期内数据,未涵盖更长随访。
  • 研究在香港进行,成本效果结果外推至其他医疗系统需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy (CIPN) in Hong Kong. METHODS: A within trial cost-utility analysis with the primary endpoint for the economic evaluation being the Quality Adjusted Life Year (QALY) and associated Incremental Cost Effectiveness Ratio (ICER) over 14 weeks of treatment. A secondary cost-effectiveness analysis was undertaken with the endpoint being change in pain as measured on the Brief Pain Inventory (BPI). RESULTS: Eighty-seven patients were randomised to acupuncture or usual care. Acupuncture resulted in significant improvements in pain intensity (8- and 14-week mean changes compared to usual care of -1.8 and -1.8, respectively), pain interference (8- and 14-week mean changes compared to usual care of -1.5 and -0.9, respectively) and indicators of quality of life and neurotoxicity-related symptoms. However, in the economic evaluation there was little difference in QALYs between the two arms (mean change 0.209 and 0.200 in the acupuncture and usual care arms, respectively). Also, costs yielded deterministic ICERs of HK$616,965.62, HK$824,083.44 and HK$540,727.56 per QALY gained from the health care provider perspective, the societal perspective and the patient perspective, respectively. These costs are significantly higher than the cost-effectiveness threshold of HK$180,450 that was used for the base case analysis. CONCLUSION: While acupuncture can improve symptoms and quality of life indicators related to CIPN, it is unlikely to be a cost-effective treatment for CIPN-related pain in health care systems with limited resources. TRIAL REGISTRATION NUMBER: NCT02553863 (ClinicalTrials.gov) post-results.

来源:Acupunct Med,查看原文。版权归原作者所有。

引用

  1. Molassiotis A, Dawkins B, Longo R, et al. Economic evaluation alongside a randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Acupunct Med. 2020. PMID: 32404001. doi:10.1177/0964528420920285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。